Should I buy or sell DURECT stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DRRX shares. View DRRX analyst ratings or view top-rated stocks .

What is DURECT's stock price target for 2024?

5 Wall Street research analysts have issued 1-year target prices for DURECT's stock. Their DRRX share price targets range from $5.00 to $41.00. On average, they predict the company's stock price to reach $27.50 in the next twelve months. This suggests a possible upside of 3,356.1% from the stock's current price. View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts .

How have DRRX shares performed in 2024?

DURECT's stock was trading at $0.59 on January 1st, 2024. Since then, DRRX shares have increased by 34.9% and is now trading at $0.7957. View the best growth stocks for 2024 here .

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our DRRX earnings forecast .

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10. The specialty pharmaceutical company had revenue of $2.17 million for the quarter, compared to analysts' expectations of $2.18 million. DURECT had a negative net margin of 323.16% and a negative trailing twelve-month return on equity of 316.78%. During the same period last year, the firm earned ($0.50) earnings per share.

When did DURECT's stock split?

Shares of DURECT reverse split before market open on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN) , Catalyst Pharmaceuticals (CPRX) , VBI Vaccines (VBIV) , MannKind (MNKD) , Novavax (NVAX) , Cassava Sciences (SAVA) , Amarin (AMRN) , Matinas BioPharma (MTNB) , Inovio Pharmaceuticals (INO) and Verastem (VSTM) .

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:DRRX

DURECT (DRRX) Stock Price, News & Analysis

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Free DRRX Stock Alerts

$0.80

+0.03 (+3.92%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.72
▼
$0.80
50-Day Range: $0.71
▼
$1.37
52-Week Range: $0.47
▼
$7.46

Volume: 86,211 shs
Average Volume: 197,516 shs
Market Capitalization: $24.70 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.50

Get DURECT alerts:

DURECT MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 3,356.1% Upside
$27.50 Price Target
Short Interest: Healthy
3.55% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.19
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.04) to ($0.75) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.92 out of 5 stars

Medical Sector

214th out of 929 stocks

Pharmaceutical Preparations Industry

87th out of 422 stocks

3.3

Analyst's Opinion

Consensus Rating
DURECT has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
DURECT has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.55% of the float of DURECT has been sold short.
Short Interest Ratio / Days to Cover
DURECT has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in DURECT has recently decreased by 0.96%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
DURECT does not currently pay a dividend.
Dividend Growth
DURECT does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
DURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for DURECT is -1.19.

3.8

News and Social Media Coverage

News Sentiment
DURECT has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for DURECT this week, compared to 1 article on an average week.
Search Interest
9 people have searched for DRRX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.
MarketBeat Follows
10 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DURECT insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of DURECT is held by insiders.
Percentage Held by Institutions
Only 28.03% of the stock of DURECT is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for DURECT are expected to grow in the coming year, from ($1.04) to ($0.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DURECT is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DURECT is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DURECT has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About DURECT Stock (NASDAQ:DRRX)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DRRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DRRX Stock News Headlines

April 1, 2024 | finance.yahoo.com

DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript

March 27, 2024 | benzinga.com

Durect: Q4 Earnings Insights

April 16, 2024 | Paradigm Press (Ad)

Biden out June 13; Kamala won’t replace him?

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

March 27, 2024 | markets.businessinsider.com

DURECT Corp. Q4 Loss decreases, beats estimates

March 27, 2024 | finance.yahoo.com

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 27, 2024 | msn.com

Options Volatility and Implied Earnings Moves Today, March 27, 2024

March 27, 2024 | msn.com

DURECT Q4 2023 Earnings Preview

March 20, 2024 | finance.yahoo.com

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

April 16, 2024 | Paradigm Press (Ad)

Biden out June 13; Kamala won’t replace him?

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

March 20, 2024 | prnewswire.com

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

March 16, 2024 | finance.yahoo.com

DRRX Apr 2024 5.000 call

March 16, 2024 | finance.yahoo.com

DRRX Apr 2024 0.500 put

March 4, 2024 | markets.businessinsider.com

DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

March 4, 2024 | msn.com

DURECT and Charles River enter agreement for alzet in U.S., Canada

March 4, 2024 | finance.yahoo.com

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

February 24, 2024 | finance.yahoo.com

DRRX Mar 2024 1.500 put

February 7, 2024 | finance.yahoo.com

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 29, 2024 | msn.com

Earth Science Tech to effect up to $5M stock repurchase program

November 16, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Taysha Gene Therapies (TSHA) and Durect (DRRX)

November 15, 2023 | seekingalpha.com

DURECT: Reading Into AHFIRM Mortality Rates

November 13, 2023 | benzinga.com

Recap: Durect Q3 Earnings

November 13, 2023 | finance.yahoo.com

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

November 12, 2023 | morningstar.com

Durect Corp DRRX

November 10, 2023 | benzinga.com

4DRRX : Durect Earnings Preview

November 10, 2023 | msn.com

JonesTrading Downgrades Durect (DRRX)

November 9, 2023 | finance.yahoo.com

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

November 9, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Durect (DRRX) and Praxis Precision Medicines (PRAX)

See More Headlines

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2021
Today: 4/15/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:DRRX
CUSIP: N/A
CIK: 1082038
Web: www.durect.com
Phone: (408) 777-1417
Fax: 408-777-3577
Employees: 58
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.50
High Stock Price Target: $41.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +3,356.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,620,000.00
Net Margins: -323.16%
Pretax Margin: -323.16%
Return on Equity: -316.78%
Return on Assets: -76.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.28
Quick Ratio: 1.20

Sales & Book Value

Annual Sales: $8.55 million
Price / Sales: 2.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 1.59

Miscellaneous

Outstanding Shares: 31,040,000
Free Float: 29,701,000
Market Cap: $24.70 million
Optionable: Optionable
Beta: 0.85

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. James E. Brown D.V.M. (Age 67)
Co-Founder, CEO, President & Director
Comp: $633.46k
Mr. Timothy M. Papp M.B.A. (Age 48)
CFO & Secretary
Comp: $427.62k
Dr. Norman L. Sussman M.D. (Age 71)
Chief Medical Officer
Comp: $471.71k
Ms. Judy R. Joice (Age 67)
Senior Vice President of Operations & Corporate Quality Assurance
Comp: $451.82k
Dr. WeiQi Lin M.D.
Ph.D., Executive VP of Research & Development and Principal Scientist
Mr. Keith L. Lui M.B.A.
Senior Vice President of Business Development, Commercial & Medical Affairs
Ms. Jian Li M.B.A. (Age 54)
Senior VP of Finance, Corporate Controller & Secretary
Comp: $297.08k
Dr. Su Il Yum Ph.D. (Age 85)
Executive Officer
Comp: $331.74k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DRRX Stock Analysis - Frequently Asked Questions

Should I buy or sell DURECT stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DRRX shares.
View DRRX analyst ratings or view top-rated stocks.
What is DURECT's stock price target for 2024?: 5 Wall Street research analysts have issued 1-year target prices for DURECT's stock. Their DRRX share price targets range from $5.00 to $41.00. On average, they predict the company's stock price to reach $27.50 in the next twelve months. This suggests a possible upside of 3,356.1% from the stock's current price.
View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts.
How have DRRX shares performed in 2024?: DURECT's stock was trading at $0.59 on January 1st, 2024. Since then, DRRX shares have increased by 34.9% and is now trading at $0.7957.
View the best growth stocks for 2024 here.
When is DURECT's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our DRRX earnings forecast.

How were DURECT's earnings last quarter?: DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10. The specialty pharmaceutical company had revenue of $2.17 million for the quarter, compared to analysts' expectations of $2.18 million. DURECT had a negative net margin of 323.16% and a negative trailing twelve-month return on equity of 316.78%. During the same period last year, the firm earned ($0.50) earnings per share.
When did DURECT's stock split?: Shares of DURECT reverse split before market open on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of DURECT own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).
How do I buy shares of DURECT?: Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRRX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial